Fig. 6: FERscores in the role of efficacy of various breast cancer therapies.
From: Efficacy of FERscore in predicting sensitivity to ferroptosis inducers in breast cancer
A Distribution of FERscores in distinct clinical response groups to neoadjuvant letrozole for ER+ breast cancer patients. B–E Distribution of FERscores in distinct anti-HER2 clinical response groups for HER2+ patients (neoadjuvant therapy regimens: T-DM1 + pertuzumab or paclitaxel + trastuzumab ± pertuzumab). F–I Distribution of FERscores in distinct clinical response groups to PD-L1 blockade, PARP inhibition and collaborative anti-angiogenesis therapy (In GSE173839: neoadjuvant durvalumab with olaparib and paclitaxel therapy; AMG 386: trebananib, an inhibitor of ANG1/2-Tie2 interaction; ABT 888: veliparib, an inhibitor of both PARP-1 and PARP-2). J–L Distribution of FERscores in distinct clinical response groups to chemotherapy in breast cancer (neoadjuvant therapy regimens: doxorubicin + cyclophosphamide followed by ixabepilone or paclitaxel in GSE41998; taxane-based chemotherapy in GSE163882; taxane-anthracycline chemotherapy in GSE25066). Box-and-whisker plots indicate median; 25th and 75th percentiles; whiskers, minima and maxima of the distributions; and the Wilcoxon signed rank test was used.
